Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.

Schubart A, Anderson K, Mainolfi N, Sellner H, Ehara T, Adams CM, Mac Sweeney A, Liao SM, Crowley M, Littlewood-Evans A, Sarret S, Wieczorek G, Perrot L, Dubost V, Flandre T, Zhang Y, Smith RJH, Risitano AM, Karki RG, Zhang C, Valeur E, Sirockin F, Gerhartz B, Erbel P, Hughes N, Smith TM, Cumin F, Argikar UA, Haraldsson B, Mogi M, Sedrani R, Wiesmann C, Jaffee B, Maibaum J, Flohr S, Harrison R, Eder J.

Proc Natl Acad Sci U S A. 2019 Apr 16;116(16):7926-7931. doi: 10.1073/pnas.1820892116. Epub 2019 Mar 29.

2.

Targeted delivery of antisense oligonucleotides to pancreatic β-cells.

Ämmälä C, Drury WJ 3rd, Knerr L, Ahlstedt I, Stillemark-Billton P, Wennberg-Huldt C, Andersson EM, Valeur E, Jansson-Löfmark R, Janzén D, Sundström L, Meuller J, Claesson J, Andersson P, Johansson C, Lee RG, Prakash TP, Seth PP, Monia BP, Andersson S.

Sci Adv. 2018 Oct 17;4(10):eaat3386. doi: 10.1126/sciadv.aat3386. eCollection 2018 Oct.

3.

Inhibition of low-density lipoprotein receptor degradation with a cyclic peptide that disrupts the homodimerization of IDOL E3 ubiquitin ligase.

Leitch EK, Elumalai N, Fridén-Saxin M, Dahl G, Wan P, Clarkson P, Valeur E, Pairaudeau G, Boyd H, Tavassoli A.

Chem Sci. 2018 Jun 26;9(27):5957-5966. doi: 10.1039/c8sc01186a. eCollection 2018 Jul 21.

4.

New Modalities, Technologies, and Partnerships in Probe and Lead Generation: Enabling a Mode-of-Action Centric Paradigm.

Valeur E, Jimonet P.

J Med Chem. 2018 Oct 25;61(20):9004-9029. doi: 10.1021/acs.jmedchem.8b00378. Epub 2018 Jun 13.

PMID:
29851477
5.

Structure-based design and synthesis of macrocyclic human rhinovirus 3C protease inhibitors.

Namoto K, Sirockin F, Sellner H, Wiesmann C, Villard F, Moreau RJ, Valeur E, Paulding SC, Schleeger S, Schipp K, Loup J, Andrews L, Swale R, Robinson M, Farady CJ.

Bioorg Med Chem Lett. 2018 Mar 1;28(5):906-909. doi: 10.1016/j.bmcl.2018.01.064. Epub 2018 Feb 1.

PMID:
29433930
6.

Directing evolution: the next revolution in drug discovery?

Davis AM, Plowright AT, Valeur E.

Nat Rev Drug Discov. 2017 Oct;16(10):681-698. doi: 10.1038/nrd.2017.146. Epub 2017 Sep 22. Review.

PMID:
28935911
7.

New Modalities for Challenging Targets in Drug Discovery.

Valeur E, Guéret SM, Adihou H, Gopalakrishnan R, Lemurell M, Waldmann H, Grossmann TN, Plowright AT.

Angew Chem Int Ed Engl. 2017 Aug 21;56(35):10294-10323. doi: 10.1002/anie.201611914. Epub 2017 Jul 24. Review.

PMID:
28186380
8.

Targeted delivery for regenerative medicines: an untapped opportunity for drug conjugates.

Valeur E, Knerr L, Ölwegård-Halvarsson M, Lemurell M.

Drug Discov Today. 2017 Jun;22(6):841-847. doi: 10.1016/j.drudis.2016.12.004. Epub 2016 Dec 14.

PMID:
27988360
9.

Therapeutic Potential of Foldamers: From Chemical Biology Tools To Drug Candidates?

Gopalakrishnan R, Frolov AI, Knerr L, Drury WJ 3rd, Valeur E.

J Med Chem. 2016 Nov 10;59(21):9599-9621. Epub 2016 Jul 29. Review.

PMID:
27362955
10.

Structure-based design of 7-azaindole-pyrrolidine amides as inhibitors of 11β-hydroxysteroid dehydrogenase type I.

Valeur E, Christmann-Franck S, Lepifre F, Carniato D, Cravo D, Charon C, Bozec S, Musil D, Hillertz P, Doare L, Schmidlin F, Lecomte M, Schultz M, Roche D.

Bioorg Med Chem Lett. 2012 Sep 15;22(18):5909-14. doi: 10.1016/j.bmcl.2012.07.070. Epub 2012 Jul 31.

PMID:
22901389
11.

Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.

Hardcastle IR, Liu J, Valeur E, Watson A, Ahmed SU, Blackburn TJ, Bennaceur K, Clegg W, Drummond C, Endicott JA, Golding BT, Griffin RJ, Gruber J, Haggerty K, Harrington RW, Hutton C, Kemp S, Lu X, McDonnell JM, Newell DR, Noble ME, Payne SL, Revill CH, Riedinger C, Xu Q, Lunec J.

J Med Chem. 2011 Mar 10;54(5):1233-43. doi: 10.1021/jm1011929. Epub 2011 Feb 11.

PMID:
21314128
12.

Discovery and structure-guided drug design of inhibitors of 11beta-hydroxysteroid-dehydrogenase type I based on a spiro-carboxamide scaffold.

Lepifre F, Christmann-Franck S, Roche D, Leriche C, Carniato D, Charon C, Bozec S, Doare L, Schmidlin F, Lecomte M, Valeur E.

Bioorg Med Chem Lett. 2009 Jul 1;19(13):3682-5. doi: 10.1016/j.bmcl.2009.02.123. Epub 2009 Mar 5.

PMID:
19450980
13.

Discovery and structure-activity relationships of pentanedioic acid diamides as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type I.

Roche D, Carniato D, Leriche C, Lepifre F, Christmann-Franck S, Graedler U, Charon C, Bozec S, Doare L, Schmidlin F, Lecomte M, Valeur E.

Bioorg Med Chem Lett. 2009 May 15;19(10):2674-8. doi: 10.1016/j.bmcl.2009.03.140. Epub 2009 Apr 1.

PMID:
19395260
14.

Amide bond formation: beyond the myth of coupling reagents.

Valeur E, Bradley M.

Chem Soc Rev. 2009 Feb;38(2):606-31. doi: 10.1039/b701677h. Epub 2008 Dec 4. Review.

PMID:
19169468
15.

Analysis of chemical shift changes reveals the binding modes of isoindolinone inhibitors of the MDM2-p53 interaction.

Riedinger C, Endicott JA, Kemp SJ, Smyth LA, Watson A, Valeur E, Golding BT, Griffin RJ, Hardcastle IR, Noble ME, McDonnell JM.

J Am Chem Soc. 2008 Nov 26;130(47):16038-44. doi: 10.1021/ja8062088.

PMID:
18959403
16.

PS-IIDQ: an efficient polymer-supported amide coupling reagent.

Valeur E, Bradley M.

Chem Commun (Camb). 2005 Mar 7;(9):1164-6. Epub 2005 Jan 17.

PMID:
15726179
17.

[Hoarseness from the viewpoint of primary care].

Järhult B, Persson GB, Valeur E.

Nord Med. 1983;98(2):35-9. Swedish.

PMID:
6828367
18.

[Possibilities in the use of hearing aids].

Bergenståhl V, Valeur E.

Lakartidningen. 1966 Jan 5;63(1):57-62. Swedish. No abstract available.

PMID:
5915952

Supplemental Content

Loading ...
Support Center